Invention Grant
- Patent Title: Nanoparticle complexes of paclitaxel, trastuzumab, and albumin
-
Application No.: US15412536Application Date: 2017-01-23
-
Publication No.: US10279035B2Publication Date: 2019-05-07
- Inventor: Svetomir N. Markovic , Wendy K. Nevala
- Applicant: Mayo Foundation for Medical Education and Research
- Applicant Address: US MN Rochester
- Assignee: Mayo Foundation for Medical Education and Research
- Current Assignee: Mayo Foundation for Medical Education and Research
- Current Assignee Address: US MN Rochester
- Agency: Myers Bigel, P.A.
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/32 ; A61K45/06 ; A61K31/337 ; C07K16/22 ; C07K16/28 ; A61K33/24 ; A61K31/555 ; A61K9/00 ; A61K9/51 ; A61K41/00 ; C07K16/30 ; A61K47/69 ; A61K47/68 ; A61K9/14 ; A61K31/282 ; A61K47/64 ; B82Y5/00 ; A61K39/00
Abstract:
This invention relates to antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g., HER2 binding specificity), for the purpose of providing cancer (e.g., HER2-related cancer) treatments in a subject in need thereof.
Public/Granted literature
- US20170196831A1 NANOPARTICLE COMPLEXES OF PACLITAXEL, ANTI-HER2 ANTIBODY, AND ALBUMIN Public/Granted day:2017-07-13
Information query
